branch of the trigeminal nerve in affected horses compared to control horses. 1, 2 Results from such studies described a functional rather than anatomical abnormality, hence the name trigeminal-mediated headshaking. 1, 9, 10 This disorder has been reported in young, mature horses of several breeds, with a predominance of cases in geldings (72%). 3, 5, 6 Head-shaking behavior appears to have a seasonal predominance in 60% of horses, with peaks during the spring and summer months. 3 Various treatments have been attempted, including nose nets, ultraviolet protective masks, nutritional supplements, drug treatment, nerve blocks, neurectomy or nerve compression, and electrical neuromodulation of the infraorbital nerve, but results have been inconsistent. [11] [12] [13] [14] [15] [16] [17] Anecdotally, magnesium supplementation leads to a decrease in head-shaking signs in 40% of affected horses. 9, 18 Magnesium is the second most abundant intracellular cation, and it participates in >300 biochemical reactions including ATPase-dependent ion pumps. 19, 20 Intracellular and extracellular fluid magnesium concentrations play a role in the transmission of nerve impulses and might result in neuroprotective effects. [21] [22] [23] [24] Intravenous infusion of MgSO 4 has many uses in horses, including treatment for hypomagnesemia, and decreasing intraoperative and postoperative pain. It also has been used in humans as a treatment for neuropathic pain with variable results. 4, 19, 23, [25] [26] [27] Horses affected by trigeminal-mediated headshaking do not show signs of hypomagnesemia, although 50%-60% of affected horses may have ionized magnesium (Mg 2+ ) concentrations below the reference range. 28 The objective of our study was to investigate the effect of an IV infusion of magnesium on head-shaking behavior in horses with trigeminal-mediated headshaking. Infusion of MgSO 4 would be expected to temporarily increase blood magnesium concentrations. 25, 27 We hypothesized that the infusion of MgSO 4 would increase total (tMg) and ionized (Mg 2+ ) magnesium concentrations in the blood and decrease head-shaking behavior.
| MATERIALS AND METHODS

| Animals
Six geldings with naturally occurring head shaking donated to the Center for Equine Health were included in the study. Inclusion criteria consisted of fulfillment of the diagnosis of trigeminal-mediated head-
shaking by exclusion of all other known causes of head shaking as described elsewhere. 9 Horses included were Quarter Horses (n = 4) and Thoroughbreds (n = 2), aged 5-13 years, and weighing between 472 and 580 kg. At the time of donation, horses had received all recommended vaccinations and deworming as per the Center for Equine Health protocols. These horses were known to be seasonal head shakers and had been donated because they were refractory to various treatments including antihistamines for possible allergies.
These horses displayed head-shaking behavior at the time of the study. The horses underwent thorough physical and neurologic examinations performed by a board-certified large animal internist and neurologist, followed by a thorough diagnostic investigation. Diagnostic evaluation included oral, ophthalmic, and otoscopic examinations, CBC, serum biochemical profile, skull radiographs, and upper airway endoscopy including evaluation of the guttural pouches. Furthermore, none of the horses had apparent cervical or nuchal pain based on palpation, extension, and flexion of the neck that could have contributed to head-shaking behavior. Computed tomography of the head to eliminate other causes was not performed. Based on historical seasonal head shaking, observed head-shaking behavior by the authors during spring and summer, and lack of abnormal findings on various diagnostic modalities, the authors believed that all of these features supported a clinical diagnosis of trigeminal-mediated headshaking.
Furthermore, it is unlikely that these horses would have had abnormalities manifested in an intermittent fashion during spring and summer months. Horses were housed in 5 × 12 ft covered stalls that contained automatic watering devices (water provided free choice) and raised metal bins for hay. Horses were fed twice daily at 7:00 AM and 5:00 PM. Stalls were cleaned and bedded with shavings daily.
| Experimental design
The study had a randomized, controlled crossover experimental design, in which each horse served as its own control. The horses were randomized to 1 of the 2 treatment groups, with a washout period of >1 week between treatments. The entire study took place over 5 weeks in the early summer to avoid seasonal and environmental variability. All horses received both treatments. An IV catheter was placed in the left jugular vein using aseptic technique. Horses received sterile fluids IV: the Dextrose Solution (DS) group received 5% dextrose solution at 2 mL/kg body weight (BW), and the Magnesium Sulfate Solution (MSS) group received 50% MgSO 4 solution at 40 mg/kg BW diluted in 5% dextrose solution. The infusion time was 5-10 minutes, and after infusion the catheter was removed.
| Sample collection
Heparinized blood samples were collected by venipuncture from the right jugular vein at T0 (baseline, before infusion) and T5, T15, T30, T60, and T120 minutes post-infusion and placed on ice immediately. A P-value <.05 was considered significant. A plot with the regression line was used to display longitudinal data for individual horses.
| Blood analysis
3 | RESULTS
| Blood results
After the infusion of MSS, Mg At baseline, all blood variables measured were within reference range with a few exceptions (Tables 1 and 2 ). Standard base excess uniformly was above reference range (mean, 6.1 ± 1.2 mmol/L for DS; 6.5 ± 1.5 mmol/L for MSS; Table 1 ), and Cl − was above reference range at baseline (mean, 103 ± 1.7 mmol/L for DS; 103 ± 1.9 mmol/L for MSS; Table 1 ). Anion gap was below reference range at baseline (mean, 7.9 ± 1.8 mmol/L for DS; 4.4 ± 1.8 mmol/L for MSS; Table 2 ).
Sodium was below reference range in MSS only (mean, 134 ± 3.4 mmol/L; Table 1 ). For MSS, SID was above reference range at baseline (mean, 37.7 ± 2.3 mmol/L; Table 2 ). For MSS, the baseline measurement for Mg 2+ was below reference range (mean, 0.42 ± 0.05 mmol/L; Table 1 ). Overall, no changes in blood pH, HCO 3 − , and SBE after DS were observed ( Table 1 ).
The DS group experienced a decrease in Na + at T5 (mean, Table 4 ).
There was an effect of canter and MSS treatment, while controlling for time and breed, with a 13-fold increase in median head shakes/minute (IRR, 13.400; CI, 7.04-25.48; P < .001; Table 4 ) as compared to first walk. There was an effect of time while controlling for treatment, breed, and gait on median head shakes/minute with T60 having 0.77 times the rate of head shaking as compared to T0 or a 24% decrease in head shaking (IRR, 0.765; CI, 0.60-0.96; P = .02). There was an effect of time when restricted to DS treatment and controlling for gait and breed with a 37% increase in median head shakes/minute at T120 (IRR, 1.367; CI, 1.02-1.83; P = .04; Table 5 ). There was an effect of time at T30 when restricted to MSS treatment and controlling for gait and breed with 0.64 times the rate of head shaking as compared to T0 or a 36% decrease in head shaking (IRR, 0.644; CI, 0.46-0.90; P = .01; Table 5 ).
There was an effect of time at T60 when restricted to MSS treatment and controlling for gait and breed with 0.47 times the rate of head shaking compared to T0 or a 53% decrease in head shaking (IRR, 0.471; CI, 0.33-0.68; P < .001; Table 5 ). There was an effect of time at T120 when restricted to MSS treatment and controlling for gait and breed with 0.48 times the rate of head shaking as compared to T0 or a 52% decrease in head shaking (0.483 IRR; CI, 0.33-0.69, P < .001, Table 5 ).
Thoroughbreds had a numerically greater reduction in head shakes per minute in response to MSS treatment compared to Quarter Horses, but the limited number of animals of each breed in the study did not permit statistical comparison.
There was a significant interaction between treatment and time while controlling for treatment, gait, and breed with MSS and T30 having 0.62 times the rate of head shaking compared to DS and T0 or a 38% decrease in head shaking (IRR, 0.620; CI, 0.39-0.98; P = .04).
There was a significant interaction between treatment and time while controlling for treatment, gait, and breed with MSS and T60 having 0.43 times the rate of head shaking compared to DS and T0 or a 57% decrease in head shaking (IRR, 0.432; CI, 0.27-0.70; P = .001). There was a significant interaction between treatment and time while controlling for treatment, gait, and breed with MSS and T120 having 0.35 
| Agreement between evaluators
Spearman's correlation was used to assess interobserver variability among the 3 evaluators. There was a strong agreement between observer 1 and 2 (r s = 0.94; P < .0001), observer 1 and 3 (r s = 0.84; P < .0001), and observer 2 and 3 (r s = 0.88; P < .0001).
| DISCUSSION
We evaluated the effects on head-shaking behavior of IV administration of MSS. These effects were expected to be observed over a short time frame because of the blood and tissue distribution of the solutions after a single infusion. The MSS treatment induced a 29% decrease in median head shakes/minute when compared to DS across all gaits (first walk, trot, canter, second walk). As exercise intensity increased from walk to trot to canter, median head shakes/minute also increased, suggesting that exercise might have contributed to the triggering or exacerbation of the observed signs in horses affected with trigeminal-mediated headshaking. Similar observations have been reported anecdotally, and our study results support this assumption. 6, 18 The largest decrease in head shakes/minute was 51% for the canter in MSS. The faster the gait, the larger the decrease in median head shakes/minute after MSS treatment. Therefore, our study highlights the possible blunting effects of magnesium during faster gaits that are likely to exacerbate head-shaking signs. An important finding is the effect of MSS treatment on decreasing median head shakes/minute starting at T30 and continuing to T120. This blunting effect might have persisted longer than our study period of 2 hours. Therefore, further evaluation to determine how long this blunting effect persists is warranted. Although there was a larger decrease in the rate of head shaking in Thoroughbreds compared to Quarter Horses in this study, the low number of horses per breed precluded any conclusion with respect to the effect of breed in the response to MSS treatment in head shaking.
Treatment with MSS supplied a large bolus of magnesium that should be 100% bioavailable. Potential adverse effects such as sweating, agitation, muscle fasciculations, arrhythmias, and collapse resulting from the infusion of MSS were not detected in any of these horses. 29 However, the dosage of magnesium used in our study was below that previously associated with toxicity in horses (1500-2000 mg/kg of PO MgSO 4 ). 29 Infusion of MSS corrected the lower concentrations of Mg 2+ observed at baseline, which also was seen in a previous study of horses affected by trigeminal-mediated headshaking. 28 The decrease in head-shaking behavior could be a result of Mg 2+ inhibiting nerve transmission. 30 Such inhibition can occur when Mg 2+ acts as a blocking agent to N-methyl-D-aspartate (NMDA) receptors, which have been shown to have an effect on trigeminal neurons at the trigeminal subnucleus caudalis (ie, the orofacial nociceptive processing center) in rats. 30 The NMDA receptors are a subtype of glutamate receptors and, once activated, are permeable to calcium and other cations. [30] [31] [32] Magnesium and zinc can bind to the NMDA receptor and prevent activation. 31, 32 Magnesium also is involved in the regulation of neuroexcitation and can inhibit Ca
2+
-dependent presynaptic excitation-secretion coupling. 22 Magnesium also participates in neuromuscular blockade by inhibiting calcium channels, which inhibits acetylcholine release and muscle excitability. 23 Furthermore, magnesium has been utilized in anesthesia as an analgesic agent. 23, 33 The exact mechanism of how magnesium acts as a pain reducer is not known but may involve inhibition of neurotransmission by blockade of receptors involved in cell excitation. 22, 31, 32 Intravenous magnesium supplementation in our study was expected to have short-acting effects on magnesium concentrations and head shaking as fluid distribution occurred in the body. However, magnesium concentrations increased and remained increased 120 minutes after infusion. The time required for normalization of plasma magnesium concentrations after infusion was not determined in our study.
Some preexisting differences in baseline blood variables were present in horses of both treatment groups. horses. Furthermore, effects of riding, tack, and rider expertise were not evaluated in our study.
In conclusion, the administration of MSS IV increased tMg and Mg 2+ and significantly decreased head-shaking behavior in horses with trigeminal-mediated headshaking. Our study supports anecdotal reports of the perceived benefits of magnesium supplementation in affected horses. Therefore, future studies should investigate practical PO supplementation of magnesium with high bioavailability would be associated with the prevention of or decrease in head shaking in affected horses.
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